Dr. Harold J. Burstein on CDK4/CDK6 Inhibitor Abemaciclib in Breast Cancer

Harold J. Burstein, MD, PhD
Published: Saturday, Aug 06, 2016


Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.
 
CDK4/CDK6 inhibitors, like abemaciclib, are a new class of drugs being investigated in advanced ER-positive breast cancer, said Burstein
 
In the study, the drug was shown to be reasonably well tolerated with some mild neutropenia and some incidence of lower GI-toxicity and diarrhea.
 
Abemaciclib induced a response rate of 19% in this patient population. The median progression-free survival (PFS) was six months and the median overall survival (OS) was 17.7 months.    
 
 

Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.
 
CDK4/CDK6 inhibitors, like abemaciclib, are a new class of drugs being investigated in advanced ER-positive breast cancer, said Burstein
 
In the study, the drug was shown to be reasonably well tolerated with some mild neutropenia and some incidence of lower GI-toxicity and diarrhea.
 
Abemaciclib induced a response rate of 19% in this patient population. The median progression-free survival (PFS) was six months and the median overall survival (OS) was 17.7 months.    
 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x